1. Home
  2. ACN vs JNJ Comparison

ACN vs JNJ Comparison

Compare ACN & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Accenture plc (Ireland)

ACN

Accenture plc (Ireland)

N/A

Current Price

$201.09

Market Cap

129.2B

ML Signal

N/A

Logo Johnson & Johnson

JNJ

Johnson & Johnson

N/A

Current Price

$243.22

Market Cap

589.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACN
JNJ
Founded
1989
1886
Country
Ireland
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
129.2B
589.2B
IPO Year
2015
2003

Fundamental Metrics

Financial Performance
Metric
ACN
JNJ
Price
$201.09
$243.22
Analyst Decision
Buy
Buy
Analyst Count
21
18
Target Price
$293.24
$228.56
AVG Volume (30 Days)
6.5M
7.0M
Earning Date
01-01-0001
04-21-2026
Dividend Yield
3.23%
2.13%
EPS Growth
6.21
90.50
EPS
3.54
11.03
Revenue
$69,672,977,000.00
N/A
Revenue This Year
$7.08
$6.63
Revenue Next Year
$5.50
$7.23
P/E Ratio
$56.94
$22.08
Revenue Growth
7.36
N/A
52 Week Low
$188.73
$141.50
52 Week High
$326.73
$251.71

Technical Indicators

Market Signals
Indicator
ACN
JNJ
Relative Strength Index (RSI) 34.22 57.61
Support Level $188.73 $201.37
Resistance Level $258.04 $251.71
Average True Range (ATR) 7.93 4.17
MACD 1.45 -1.41
Stochastic Oscillator 41.45 48.53

Price Performance

Historical Comparison
ACN
JNJ

About ACN Accenture plc (Ireland)

Accenture is a leading IT services firm that provides consulting, system integration, and business process outsourcing to enterprises around the world. Customers of Accenture come from a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture is the world's largest professional services company by headcount with around 800,000 employees in over 120 countries.

About JNJ Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Share on Social Networks: